GoldenGolden
Gilead Sciences

Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company developing and commercializing medicines founded in 1987 by Michael L. Riordan.

Gilead Sciences is a research-based biopharmaceutical company developing and commercializing medicines that is headquartered in Foster City, California and was founded in 1987. The firm also has locations in La Vernne, California; Oceanside California; San Dimas, California; Miami, Florida; Santa Monica, California; Seattle, Washington; El Segundo, California; and Emeryville, California.

Gilead Sciences specializes in developing and commercializing biopharmaceuticals for HIV/AIDS, liver disease, hematology, oncology, inflammation, respiratory diseases, highly infectious diseases, and viral diseases. Gilead partnered with Kyverna to develop engineering T cell immunotherapies to target autoimmune diseases. The collaboration involves Kyverna’s synthetic Treg platform and synNotch, a synthetic gene expression system from the Kite unit of Gilead.

Gilead Sciences actively participates in community partnerships with COMPASS Initiative, Gilead Lift, Gilead HIV Age Positively, TRANScend, and HepConnect.

With the outbreak of COVID-19, Gilead Sciences began evaluating patients and testing remdesivir in 600 patients with moderate COVID-19 symptoms. They also began treatment of 400 patients with severe symptoms. Their results are expected in May.

Investments

Gilead Sciences has made 12 investments, 3 lead investments, and 4 exits. Notable investments made by Gilead Sciences include: Precision BioSciences, Galapagos, Phenex Pharmaceuticals, Allogene Therapeutics, National AIDS Memorial, Tmunity Therapeutics, AlloVir, Goldfinch Biopharma, Lyndra Therapeutics, and Glympse Bio. Gilead has licensed rights to filgotinib, developed by Galapagos, for rheumatoid arthritis and GLPG1690 for idiopathic pulmonary fibrosis, both in late-stage clinical studies.

Timeline

June 29, 2020
Gilead Sciences Inc announces it has set the price its Covid-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries.

Products

People

Name
Role
LinkedIn

A Deo

Employee

Aaron Arvey

Employee

Aaron Banner

Employee

Abasi Ene-Obong Ph.D.

Employee

Abrar Farooqui

Employee

Aditya Jhanwar

Employee

Adrienne Eng

Employee

Adrienne Orr

Employee

Ahmed Moussa

Employee

Akshith Mithun

Employee

Alan Stowe

Employee

Alex Derchak

Employee

Alex Iserlis

Employee

Alexandria Tong

Employee

Alexej Ladonnikov

Employee

Alexis C Glasgow

Employee

Alison Dowski

Employee

Alison Lin

Employee

Alistair Barkhouse

Employee

Aliyah Sulaiman

Employee

Ambika Gopalan

Employee

Amer Raza

Employee

Amir Abbas

Employee

Amit Vora

Employee

Amrith Mylvara

Employee

Page 1 of 16
...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Research and Markets
June 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Regenerative Medicine Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The...
BioSpace
June 15, 2021
BioSpace
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs.
Angus Liu
June 7, 2021
FierceBiotech
A Swiss biotech suggests that one of its clinical candidates, currently in late-stage development for breast cancer, may also work as a COVID-19 treatment. The drug, called balixafortide, reduced viral load of the coronavirus that causes COVID, as well as COVID-related inflammation markers, in hamsters.
BioSpace
June 3, 2021
BioSpace
Janux Therapeutics, a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Wayne Godfrey, M.D., as Chief Medical Officer, effective June 1, 2021.
BioSpace
June 1, 2021
BioSpace
Century Therapeutics , a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Alessandro Riva , M.D., and Kimberly Blackwell, M.D., as new Independent Directors.
Century Therapeutics
June 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology,...
Verified Market Research
May 31, 2021
www.prnewswire.com:443
/PRNewswire/ -- Verified Market Research recently published a report, "Active Pharmaceutical Ingredient (API) Market" By Molecule (Small Molecule and Large...
May 27, 2021
@TIMESNOW
To augment production, the government of India has given licenses to 5 more companies that can manufacture the drug.
Alex Keown
May 26, 2021
BioSpace
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
Alex Keown
May 26, 2021
BioSpace
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
BioSpace
May 26, 2021
BioSpace
The Satcher Health Leadership Institute at Morehouse School of Medicine, with support from Gilead Sciences, Inc., Google.org, the Annie E. Casey Foundation, and the CDC Foundation announced the launch of the Health Equity Tracker, a comprehensive data platform that can highlight and address the impact of COVID-19 and other diseases on the Black, Indigenous, Latinx, Asian, Pacific Islander, and other vulnerable and marginalized communities.
Satcher Health Leadership Institute
May 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- Today, the Satcher Health Leadership Institute at Morehouse School of Medicine (SHLI), with support from Gilead Sciences, Inc. (Nasdaq: GILD),...
May 17, 2021
BioSpace
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors - read this article along with other careers information, tips and advice on BioSpace
Leroy Leo
April 30, 2021
mint
Apart from Gilead's supply, India will also get remdesivir from Egypt-based Eva Pharma, with which Gilead had signed a voluntary licensing agreement in May last year.
BioSpace
April 27, 2021
BioSpace
Dr. Curley brings extensive pharmaceutical industry experience in product development, commercialization and operations as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders
Sam Roberts
April 27, 2021
www.nytimes.com
A chemist by training, he turned Gilead Sciences into a leading, and lucrative, innovator with single-pill treatments for H.I.V. and hepatitis C.
DelveInsight Business Research, LLP
April 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- DelveInsight's "Global Kinase Inhibitor in Autoimmune Diseases Market" report provides a thorough comprehension and the Global Kinase Inhibitor...
Brandon May
April 14, 2021
BioSpace
Common stock in the new combined company, Tango Therapeutics, Inc., will soon be listed on Nasdaq under ticker "TNGX."
Andrea Park
April 14, 2021
FierceBiotech
Though it was never much of a benchwarmer to begin with, Benchling has certainly hit the big leagues with its latest fundraising, the largest by far in the startup's almost decade-long history.
Everest Medicines
April 14, 2021
www.prnewswire.com:443
/PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.